This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.2.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions
Definitions for oncology-BreastCancerStageTopic-model.
oncology-BreastCancerStageTopic-model | |
Definition | The topic class for describing a breast cancer staging observation. |
Control | 0..* |
oncology-BreastCancerStageTopic-model.topicCode | |
Definition | The concept representing the finding or action that is the topic of the statement. For action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding. |
Control | 1..1 |
Type | Coding |
oncology-BreastCancerStageTopic-model.topicCode.id | |
Definition | unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces. |
Control | 0..1 |
Type | string |
oncology-BreastCancerStageTopic-model.topicCode.extension | |
Definition | May be used to represent additional information that is not part of the basic definition of the element. In order to make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer is allowed to define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. |
Control | 0..* |
Type | Extension |
Comments | There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone. |
oncology-BreastCancerStageTopic-model.topicCode.system | |
Definition | The identification of the code system that defines the meaning of the symbol in the code. |
Control | 1..1 |
Type | uri |
Requirements | Need to be unambiguous about the source of the definition of the symbol. |
Comments | The URI may be an OID (urn:oid:...) or a UUID (urn:uuid:...). OIDs and UUIDs SHALL be references to the HL7 OID registry. Otherwise, the URI should come from HL7's list of FHIR defined special URIs or it should de-reference to some definition that establish the system clearly and unambiguously. |
Fixed Value | http://ncimeta.nci.nih.gov |
oncology-BreastCancerStageTopic-model.topicCode.version | |
Definition | The version of the code system which was used when choosing this code. Note that a well-maintained code system does not need the version reported, because the meaning of codes is consistent across versions. However this cannot consistently be assured. and when the meaning is not guaranteed to be consistent, the version SHOULD be exchanged. |
Note | This is a business versionId, not a resource version id (see discussion) |
Control | 0..1 |
Type | string |
Comments | Where the terminology does not clearly define what string should be used to identify code system versions, the recommendation is to use the date (expressed in FHIR date format) on which that version was officially published as the version date. |
oncology-BreastCancerStageTopic-model.topicCode.code | |
Definition | A symbol in syntax defined by the system. The symbol may be a predefined code or an expression in a syntax defined by the coding system (e.g. post-coordination). |
Control | 1..1 |
Type | code |
Requirements | Need to refer to a particular code in the system. |
Fixed Value | C2216702 |
oncology-BreastCancerStageTopic-model.topicCode.display | |
Definition | A representation of the meaning of the code in the system, following the rules of the system. |
Control | 0..1 |
Type | string |
Requirements | Need to be able to carry a human-readable meaning of the code for readers that do not know the system. |
oncology-BreastCancerStageTopic-model.topicCode.userSelected | |
Definition | Indicates that this coding was chosen by a user directly - i.e. off a pick list of available items (codes or displays). |
Control | 0..1 |
Type | boolean |
Requirements | This has been identified as a clinical safety criterium - that this exact system/code pair was chosen explicitly, rather than inferred by the system based on some rules or language processing. |
Comments | Amongst a set of alternatives, a directly chosen code is the most appropriate starting point for new translations. There is some ambiguity about what exactly 'directly chosen' implies, and trading partner agreement may be needed to clarify the use of this element and its consequences more completely. |
oncology-BreastCancerStageTopic-model.findingMethod | |
Definition | The technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. |
Control | 0..0 |
Binding | The codes SHOULD be taken from http://loinc.org/vs |
Type | Coding |
oncology-BreastCancerStageTopic-model.details | |
Definition | A text note containing additional details, explanation, description, comment, or summarization. Details can discuss, support, explain changes to, or dispute information. |
Control | 0..1 |
Type | string |
oncology-BreastCancerStageTopic-model.media | |
Definition | A file that contains audio, video, image, or similar content. |
Control | 0..0 |
Type | http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Media-model |
oncology-BreastCancerStageTopic-model.category | |
Definition | A class or division of people or things having particular shared characteristics |
Control | 1..* |
Binding | The codes SHALL be taken from Observation Category Codes; other codes may be used where these codes are not suitable |
Type | Coding |
oncology-BreastCancerStageTopic-model.anatomicalLocation | |
Definition | A location or structure in the body, including tissues, regions, cavities, and spaces; for example, right elbow, or left ventricle of the heart. |
Control | 0..0 |
Type | http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-element-AnatomicalLocation-model |
oncology-BreastCancerStageTopic-model.device | |
Definition | A specific durable physical device used in diagnosis or treatment. The value is the coding for a type of device, for example, a CPAP machine. The same device might be used on multiple patients. |
Control | 0..0 |
Type | Reference(DeviceModel) |
oncology-BreastCancerStageTopic-model.specimen | |
Definition | A specimen is a substance, physical object, or collection of objects, that the laboratory considers a single discrete, uniquely identified unit that is the subject of one or more steps in the laboratory workflow. A specimen may include multiple physical pieces as long as they are considered a single unit within the laboratory workflow. A specimen results from one to many specimen collection procedures, and may be contained in multiple specimen containers. Specimen may have one or more processing activities. |
Control | 0..0 |
Type | Reference(SpecimenModel) |
oncology-BreastCancerStageTopic-model.precondition | |
Definition | A description of the conditions or context of an observation, for example, under sedation, fasting or post-exercise. Body position and body site are also qualifiers, but handled separately. A qualifier cannot modify the measurement type; for example, a fasting blood sugar is still a blood sugar. |
Control | 0..0 |
Type | Choice of: Coding, Reference(ObservationModel) |
oncology-BreastCancerStageTopic-model.referenceRange | |
Definition | The usual or acceptable range for a test result. |
Control | 0..0 |
Type | http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model |
oncology-BreastCancerStageTopic-model.evaluationComponent | |
Definition | A simplified, non-separable evaluation consisting of a finding code (represented by the Concept), value (or exception value), reference range, and interpretation. The subject of the evaluation component is the same as in the parent evaluation. |
Control | 0..0 |
Type | http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-EvaluationComponent-model |
oncology-BreastCancerStageTopic-model.panelMembers | |
Definition | PanelMembers represent the elements of a group of a related but independent evaluations. Examples are the measurements that compose a complete blood count (CBC), or the elements of a pathology report. Each member is an independent evaluation, but the grouping reflects a composite lab order, shared specimen, or a single report author. Typically the Category and Reason are not given for individual findings that are part of the panel, but rather given at the level of the panel itself. |
Control | 0..1 |
Type | BackboneElement |
oncology-BreastCancerStageTopic-model.panelMembers.observation | |
Definition | Represents the result of evaluations (measurements, tests, or questions) that have been performed. Observation has a value representing the result (answer), or an ExceptionValue indicating why the value is not present. The subject of a finding can be the entire patient, or an entity such as a location body structure, intervention, or condition. Things observed about the subject can include social and behavioral factors, subjective and objective observations, and assessments. |
Control | 0..1 |
oncology-BreastCancerStageTopic-model.panelMembers.observation.breastCancerPrimaryTumorClassification | |
Definition | The size and extent of the primary tumor, based on criteria defined by the staging system being used. |
Control | 0..1 |
Type | Reference(BreastCancerPrimaryTumorClassificationModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.breastCancerRegionalNodesClassification | |
Definition | The presence of metastases in regional lymph nodes, based on criteria defined by the staging system being used. |
Control | 0..1 |
Type | Reference(BreastCancerRegionalNodesClassificationModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.breastCancerDistantMetastasesClassification | |
Definition | The presence of distant metastases, based on criteria defined by the staging system being used. |
Control | 0..1 |
Type | Reference(BreastCancerDistantMetastasesClassificationModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.hER2ReceptorStatus | |
Definition | HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors, and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options. |
Control | 0..1 |
Type | Reference(HER2ReceptorStatusModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.estrogenReceptorStatus | |
Definition | Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence (NuclearPositivity and AverageStainingIntensity). |
Control | 0..1 |
Type | Reference(EstrogenReceptorStatusModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.progesteroneReceptorStatus | |
Definition | Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity. Based on discussion with Cancer Interoperability Group subject matter experts, there was insufficient rationale to include the following components in the data model: StainingControl, PrimaryAntibody, Allred Score (both total and component scores). We are seeking feedback on whether or not those components should be included in this model. |
Control | 0..1 |
Type | Reference(ProgesteroneReceptorStatusModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.dCISNuclearGrade | |
Definition | An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade. In breast cancer, nuclear grade is typically evaluated for ductal carcinoma in situ (DCIS) only. There is currently no concept code for DCIS Nuclear Grade in LOINC, SNOMED, or NCI Metathesaurus. |
Control | 0..1 |
Type | Reference(DCISNuclearGradeModel) |
oncology-BreastCancerStageTopic-model.panelMembers.observation.breastCancerHistologicGrade | |
Definition | The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated cells (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing. |
Control | 0..1 |
Type | Reference(BreastCancerHistologicGradeModel) |
oncology-BreastCancerStageTopic-model.stageTimingPrefix | |
Definition | Indicates when the staging was done, in terms of treatment landmarks. |
Control | 0..1 |
Binding | The codes SHALL be taken from StageTimingPrefixVS |
Type | Coding |